Get the Stockscreener App
89.35
1.08%
-1.55
Lantheus Holdings Inc stock is traded at $89.35, with a volume of 234.79K.
It is down -1.08% in the last 24 hours and down -7.22% over the past month.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
See More
Previous Close:
$90.90
Open:
$90.64
24h Volume:
234.79K
Relative Volume:
0.22
Market Cap:
$6.32B
Revenue:
$1.50B
Net Income/Loss:
$427.61M
P/E Ratio:
14.87
EPS:
6.01
Net Cash Flow:
$423.98M
1W Performance:
-2.80%
1M Performance:
-7.22%
6M Performance:
-6.43%
1Y Performance:
+64.69%
1-Day Range:
$89.50
$93.27
1-Week Range:
$87.56
$93.27
52-Week Range:
$53.47
$126.89
Lantheus Holdings Inc Stock (LNTH) Company Profile
Name
Lantheus Holdings Inc
Sector
Phone
978 671-8001
Address
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
89.50 | 6.32B | 1.50B | 427.61M | 423.98M | 6.01 |
|
ZTS
Zoetis Inc
|
171.45 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.54 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.545 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.66 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
123.64 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Buy |
| Sep-03-24 | Initiated | Redburn Atlantic | Buy |
| Jul-10-24 | Reiterated | JMP Securities | Mkt Outperform |
| Dec-18-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-04-23 | Initiated | TD Cowen | Outperform |
| Sep-29-23 | Initiated | William Blair | Outperform |
| Mar-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Nov-30-22 | Initiated | SVB Leerink | Outperform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| May-09-22 | Initiated | B. Riley Securities | Buy |
| Apr-13-22 | Initiated | Truist | Buy |
| Feb-01-21 | Initiated | SVB Leerink | Outperform |
| Jun-29-20 | Resumed | Jefferies | Buy |
| Aug-16-19 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Nov-02-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-08-16 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-23-16 | Resumed | Credit Suisse | Neutral |
| Feb-24-16 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-11-15 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-30-15 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-20-15 | Initiated | Credit Suisse | Outperform |
| Jul-20-15 | Initiated | Jefferies | Buy |
| Jul-20-15 | Initiated | RBC Capital Mkts | Outperform |
| Jul-20-15 | Initiated | Robert W. Baird | Outperform |
| Jul-20-15 | Initiated | Wells Fargo | Outperform |
View All
Lantheus Holdings Inc Stock (LNTH) Latest News
Lantheus Holdings validates Fair Value model with 59% return since January 2024 - Investing.com India
Trend Tracker for (LNTH) - Stock Traders Daily
Why Lantheus Holdings Stock Got Thrashed on Tuesday - AOL
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting - The Bakersfield Californian
Revolutionary Prostate Cancer Detection Breakthrough: Lantheus PYLARIFY Shows Success in Low PSA Patients - StockTitan
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio - MSN
Lantheus Holdings, Inc. (LNTH): Among the Best Low Risk High Growth Stocks To Invest In Now - Insider Monkey
Lantheus goes Evergreen in a $250m upfront deal - BioProcess Insider
12 Best Low Risk High Growth Stocks to Invest In - Insider Monkey
Janney Montgomery Scott LLC Grows Position in Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat
Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Position Increased by Swedbank AB - MarketBeat
SkyOak Wealth LLC Buys 5,000 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat
Lantheus (NASDAQ:LNTH) Releases FY 2024 Earnings Guidance - MarketBeat
LNTHLantheus Holdings, Inc Latest Stock News & Market Updates - StockTitan
Lantheus Appoints Dr. Morrow to Board of Directors - TipRanks
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - MSN
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., to Board - citybiz
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member - The Manila Times
Takeda's Oncology Chief Joins Lantheus Board: Major Win for Radiopharmaceutical Pipeline - StockTitan
LNTH: Evergreen Acquisition Promotes Future Innovation - Research Tree
Lantheus expands in neuro and oncology with LMI and Evergreen acquisitions - Medical Device Network
Lantheus to acquire Evergreen Theragnostics for up to $1 billion - DOTmed
Lantheus (LNTH) Stock Declines Amid Acquisition Announcement - GuruFocus.com
Lantheus Holdings Inc. Announces Strategic Acquisition of Evergr - GuruFocus.com
Lantheus to Acquire Evergreen Theragnostics for $250 Million - MSN
Items Tagged with 'Life Molecular Imaging Ltd.' - BioWorld Online
Lantheus lights up market with $1.025B Evergreen buy - BioWorld Online
Lantheus to Acquire Evergreen Theragnostics to Expand Radiopharmaceutical Capabilities - HIT Consultant
Lantheus to buy radiopharma CDMO Evergreen Theragnostics for $250M upfront - MM+M Online
Lantheus to acquire Evergreen Theragnostics - MSN
Lantheus to Acquire Evergreen Theragnostics in $1B Deal - USA Herald
Lantheus (NASDAQ:LNTH) Trading Down 5.5%Should You Sell? - MarketBeat
4 Firms Look To Build $1B Sale Of Evergreen Theragnostics - Law360
Lantheus is on a buying spree. Its latest deal is worth up to $1B - The Business Journals
Lantheus lights up market with up to $1B Evergreen buy - BioWorld Online
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio - Benzinga
Lantheus Holdings to Acquire Evergreen Theragnostics - Contract Pharma
Lantheus Holdings to Acquire Evergreen Theragnostics in All-Cash Transaction -January 28, 2025 at 06:52 am EST - Marketscreener.com
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader - PR Newswire
Lantheus to Acquire Evergreen Theragnostics for Upfront - GlobeNewswire
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive ... - The Bakersfield Californian
Major Radiopharmaceutical Deal: Lantheus's $1B Game-Changing Move Into Cancer Treatment Manufacturing - StockTitan
Goldman Sachs Initiates Coverage of Lantheus Holdings (LNTH) with Buy Recommendation - MSN
AlphaMark Advisors LLC Reduces Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat
Where are the Opportunities in (LNTH) - Stock Traders Daily
Lantheus Holdings (NASDAQ:LNTH) Seems To Use Debt Rather Sparingly - Simply Wall St
Whalen Wealth Management Inc. Buys Shares of 2,695 Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat
MinichMacGregor Wealth Management LLC Has $7.49 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now - MSN
Mitsubishi UFJ Asset Management UK Ltd. Sells 9,500 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) - MarketBeat
Lantheus Holdings Inc Stock (LNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.65%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):